Realty Income Has Raised Its Dividend 113 Consecutive Times. Here Is Why That Is Not Enough to Own It Right Now

The article argues Realty Income is overvalued at 55x trailing and 40x forward P/E, with 2026 AFFO guidance of $4.38-$4.42 implying only 2.8% midpoint growth while leverage remains elevated at 7.91x net debt/EBITDA. It highlights weak operating trends including repeated EPS misses, rising interest expense to $1.13 billion, and occupancy drifting from 98.9% to 98.5%. In contrast, AbbVie is presented as the better income choice, with Q1 2026 revenue of $15.00 billion (+12.4%), a 5.5% dividend increase to $1.73 quarterly, and a lower forward P/E of 14 versus O's 40.

Analysis

This is less a debate about dividend quality than about balance-sheet arithmetic. O’s appeal depends on the market continuing to underwrite a levered, slow-growth bond proxy at an equity multiple that leaves no margin for error; that works until rates stop falling or cap rates stop compressing. The second-order risk is that every incremental acquisition done to defend the dividend can dilute per-share growth if funding costs remain sticky, which is exactly how a “safe” monthly payer becomes a multiple trap.

ABBV is the more interesting expression because the market still prices it like a mature pharma name despite evidence that the post-Humira earnings bridge is already functioning. The real upside is not just earnings growth, but the combination of higher payout capacity and multiple re-rating if investors start valuing the dividend as a covered, expanding stream rather than a legacy-income substitute. That leaves room for both dividend-growth buyers and quality growth funds to own the same stock, which is a powerful setup when cash generation is still accelerating.

The contrarian miss on O is that the stock can stay expensive longer than fundamental investors expect if income demand remains captive and rate cuts pull yield chasers back into REITs. But the asymmetry is poor: upside likely requires a macro tailwind, while downside can be triggered by even modest misses in occupancy, rent growth, or financing spreads over the next 2-4 quarters. For ABBV, the key risk is not the current model but late-cycle pipeline disappointment; still, that is a multi-year thesis risk, not a near-term earnings problem.

Key Decisions for Investors

• Express the relative view with a pair: long ABBV / short O on a 3-6 month horizon. The trade benefits from ABBV’s covered dividend growth and lower multiple while O remains exposed to leverage and rate sensitivity; size the short smaller than the long because O can re-rate on a dovish macro turn.
• Buy ABBV on any post-earnings weakness into the low-200s for a 6-12 month hold. Risk/reward is favorable because the stock is still priced below where its earnings quality and payout durability would normally support a premium multiple.
• Avoid initiating fresh long O exposure above 40x forward earnings unless there is a clear catalyst for faster AFFO-per-share growth. If already owned for income, consider trimming into strength and redeploying into covered dividend growers with better payout coverage.
• For tactical traders, use O put spreads 3-6 months out to position for a financing-cost or guidance disappointment. The thesis only needs a small negative surprise to compress the multiple, while downside is constrained by the existing dividend support.
• If you must own REIT income, rotate toward lower-leverage, better-growth names rather than yield-maximizers. The market is increasingly rewarding dividend durability over headline yield, and that regime favors ABBV-like cash compounders over balance-sheet-sensitive net lease names.